Drug Classes Show Similar Efficacy for Preventing EIMs in HLA-B27-Associated Diseases
The probability of developing ocular EIMs was comparable across treatment classes among patients with HLA-B27-associated diseases.
Tumor necrosis factor (TNF), interleukin (IL), and Janus kinase (JAK) inhibitors demonstrate comparable efficacy for preventing ocular and extraintestinal manifestations (EIMs) among patients with human leukocyte antigen (HLA)-B27-associated diseases, according to study findings published in Clinical Rheumatology.
Ocular involvement, particularly anterior uveitis, is 1 of the most common manifestations of HLA-B27-associated diseases and may precede systemic symptoms.
Despite the frequent use of TNF, IL, and JAK inhibitors in clinical practice, large-scale comparative evidence on their efficacy for preventing ocular and systemic manifestations is limited.
To address this gap, investigators conducted a retrospective cohort study using aggregated, de-identified electronic health records from the TriNetX Global Research Network between 2014 and 2024.
No direct quote available in the text.
Author's summary: Study finds similar efficacy for TNF, IL, and JAK inhibitors in preventing EIMs.
More News
- Newest Ted's Fish Fry coming to Ballston Spa
- From service to sickness: Colorado veterans deserve a mesothelioma registry
- Popular librarian event returns to WICA | South Whidbey Record
- RCPL welcomes new adult services librarian Lauren Tubbs | Robesonian
- Waterford's Michael Whelan reflects on two-month bike trip across Asia - News - Waterford News & Star
- Can Joji, Tame Impala or Chris Brown & Usher Make Waves on the Hot 100 Next Week? | The Contenders
- Hannah's future stolen by jealous, angry act of horror